No Data
No Data
Express News | Outlook Therapeutics Inc - Restructuring Payments Expected to Be Complete by Q3 2025
Outlook Therapeutics to Cut 23% Workforce to Lower Costs
Outlook Therapeutics Streamlines Operations, Cuts Workforce By 23% For $1.4M Annual Savings, Aims To Launch LYTENAVA In EU/UK, Prepares BLA Resubmission In Q1 2025 Despite NORSE EIGHT Trial Not Meeting Endpoint; LYTENAVA Receives NICE Recommendation,...
Express News | Outlook Therapeutics Inc - to Resubmit Bla Application for Ons-5010 in Q1 2025
Express News | Outlook Therapeutics Inc - Implements Initiatives to Streamline Organization and Reduce Expenses
Outlook Therapeutics Streamlines Operations
Unlock the Full List